Oculis (NASDAQ:OCS) Raised to “Sell” at Wall Street Zen

Oculis (NASDAQ:OCS) was upgraded by Wall Street Zen from a “strong sell” rating to a “sell” rating in a note issued to investors on Saturday.

A number of other analysts also recently issued reports on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Oculis in a report on Friday, July 17th. Needham & Company LLC decreased their target price on shares of Oculis from $46.00 to $38.00 and set a “buy” rating for the company in a research report on Monday, June 1st. JPMorgan Chase & Co. lowered their price target on shares of Oculis from $42.00 to $23.00 and set an “overweight” rating on the stock in a research note on Wednesday, June 3rd. Stifel Nicolaus cut their price target on shares of Oculis from $50.00 to $40.00 and set a “buy” rating on the stock in a research report on Monday, June 1st. Finally, Robert W. Baird reduced their price objective on shares of Oculis from $49.00 to $38.00 and set an “outperform” rating for the company in a research note on Monday, June 1st. Nine research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $38.33.

Oculis Stock Performance

Shares of Oculis stock opened at $12.68 on Friday. The company has a debt-to-equity ratio of 0.01, a current ratio of 8.35 and a quick ratio of 8.35. The firm has a market cap of $735.24 million, a price-to-earnings ratio of -7.29 and a beta of 0.51. The stock’s 50-day moving average is $12.17 and its 200-day moving average is $22.29. Oculis has a one year low of $10.52 and a one year high of $34.47.

Oculis (NASDAQ:OCS) last released its earnings results on Tuesday, June 30th. The company reported ($0.20) EPS for the quarter. Oculis had a negative net margin of 6,777.18% and a negative return on equity of 42.61%. The firm had revenue of $0.38 million during the quarter. Equities analysts predict that Oculis will post -2.22 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Oculis

Institutional investors and hedge funds have recently modified their holdings of the company. China Universal Asset Management Co. Ltd. increased its position in Oculis by 100.0% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 2,000 shares of the company’s stock worth $40,000 after buying an additional 1,000 shares during the last quarter. Koshinski Asset Management Inc. acquired a new stake in shares of Oculis in the first quarter valued at approximately $238,000. Millennium Management LLC bought a new position in shares of Oculis during the 4th quarter worth approximately $312,000. Himension Capital Singapore PTE. LTD. acquired a new position in shares of Oculis during the 1st quarter worth approximately $503,000. Finally, Marshall Wace LLP acquired a new position in shares of Oculis during the 2nd quarter worth approximately $393,000. 22.30% of the stock is owned by institutional investors.

About Oculis

Oculis SA (NASDAQ: OCS) is a clinical-stage biopharmaceutical company focused on developing novel ophthalmic therapies designed primarily to treat retinal and neuro-ophthalmic diseases. Leveraging its proprietary technology platforms, Oculis aims to deliver therapeutic agents to the back of the eye through topical or nasal administration, potentially offering an alternative to current intravitreal injections. The company’s pipeline includes OCS-01, a topical dexamethasone formulation targeting diabetic macular edema; OCS-05, a neuroprotective candidate for acute optic neuritis and idiopathic intracranial hypertension; and OC-02, a nasal spray formulation of varenicline for dry eye disease.

Founded in 2016 and headquartered in Basel, Switzerland, Oculis operates research and development facilities across Europe and in the United States, with a presence in Cambridge, Massachusetts.